1
|
Venegoni C, Tortorella S, Caliendo A, Locatelli I, Coste AD, Locatelli E, Capancioni F, Bua E, Camorani S, Salonia A, Montorsi F, Jose J, Moschini M, Cerchia L, Franchini MC, Alfano M. Urine-Stable Aptamer-Conjugated Gold Nanorods for the Early Detection of High-Grade Bladder Cancer Residual Disease. Adv Healthc Mater 2025; 14:e2403314. [PMID: 39935083 PMCID: PMC12004434 DOI: 10.1002/adhm.202403314] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2024] [Revised: 11/22/2024] [Indexed: 02/13/2025]
Abstract
The limitations of current diagnostic imaging techniques and therapies for bladder cancer are associated with and responsible for the recurrence and progression of residual disease, with an impact on social costs and quality of life of patients. This study delivers a cost-effective solution for the detection of bladder cancer residual disease, which is represented by the early detection of bladder cancer lesions < 1 mm. Urine-stable 34-mer SH-terminated 2'F-Py-RNA aptamer that recognizes the integrin α5β1, expressed by 81% of human high-grade non-muscle invasive bladder cancer, is developed. The intravesical instillation of aptamer-conjugated gold nanorods as contrast agent for photoacoustic imaging is validated in a preclinical model of orthotopic bladder cancer expressing the integrin α5β1. The photoacoustic signal of gold nanorods remains on the tumor surface for 3 h and allows early detection of cancer lesions < 1 mm. The aptamer is internalized into lysosomes, an opportunity that paves the way for lysosomal-mediated drug release in tumor cells. This study highlights the potential of urine-stable aptamer for the delivery of a solution to target the residual high-grade bladder cancer disease.
Collapse
Affiliation(s)
- Chiara Venegoni
- Division of Experimental Oncology/Unit of UrologyURIIRCCS San Raffaele Scientific InstituteMilan20132Italy
| | - Silvia Tortorella
- Department of Industrial Chemistry “Toso Montanari”University of BolognaVia P. Gobetti 85Bologna40129Italy
| | - Alessandra Caliendo
- Institute of Experimental Endocrinology and Oncology "Gaetano Salvatore"National Research CouncilNaples80131Italy
| | - Irene Locatelli
- Division of Experimental Oncology/Unit of UrologyURIIRCCS San Raffaele Scientific InstituteMilan20132Italy
| | - Alessia Di Coste
- Division of Experimental Oncology/Unit of UrologyURIIRCCS San Raffaele Scientific InstituteMilan20132Italy
| | - Erica Locatelli
- Department of Industrial Chemistry “Toso Montanari”University of BolognaVia P. Gobetti 85Bologna40129Italy
| | - Filippo Capancioni
- Department of Industrial Chemistry “Toso Montanari”University of BolognaVia P. Gobetti 85Bologna40129Italy
| | - Emanuela Bua
- Department of Industrial Chemistry “Toso Montanari”University of BolognaVia P. Gobetti 85Bologna40129Italy
| | - Simona Camorani
- Institute of Experimental Endocrinology and Oncology "Gaetano Salvatore"National Research CouncilNaples80131Italy
| | - Andrea Salonia
- Division of Experimental Oncology/Unit of UrologyURIIRCCS San Raffaele Scientific InstituteMilan20132Italy
- Università Vita‐Salute San RaffaeleMilan20132Italy
| | - Francesco Montorsi
- Division of Experimental Oncology/Unit of UrologyURIIRCCS San Raffaele Scientific InstituteMilan20132Italy
- Università Vita‐Salute San RaffaeleMilan20132Italy
| | - Jithin Jose
- FUJIFILM Visualsonics Inc.Amsterdam1114 ABThe Netherlands
| | - Marco Moschini
- Division of Experimental Oncology/Unit of UrologyURIIRCCS San Raffaele Scientific InstituteMilan20132Italy
| | - Laura Cerchia
- Institute of Experimental Endocrinology and Oncology "Gaetano Salvatore"National Research CouncilNaples80131Italy
| | - Mauro Comes Franchini
- Department of Industrial Chemistry “Toso Montanari”University of BolognaVia P. Gobetti 85Bologna40129Italy
| | - Massimo Alfano
- Division of Experimental Oncology/Unit of UrologyURIIRCCS San Raffaele Scientific InstituteMilan20132Italy
| |
Collapse
|
2
|
Masanam HB, Muthuraman J, Chandra B, Kottapalli VNSM, Chandra SS, Gupta PK, Narasimhan AK. Investigation on the heating effects of intra-tumoral injectable magnetic hydrogels (IT-MG) for cancer hyperthermia. Biomed Phys Eng Express 2025; 11:025036. [PMID: 39869935 DOI: 10.1088/2057-1976/adaec6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2024] [Accepted: 01/27/2025] [Indexed: 01/29/2025]
Abstract
Capacitive-based radiofrequency (Rf) radiation at 27 MHz offers a non-invasive approach for inducing hyperthermia, making it a promising technique for thermal cancer therapy applications. To achieve focused and site-specific hyperthermia, Rf-responsive materials is required to convert Rf radiation into localized heat efficiently. Nanoparticles capable of absorbing Rf energy and convert into heat for targeted ablation are of critical importance. In this study, we developed and evaluated an Intra-tumoral injectable magnetic hydrogel (IT-MG) composed of Superparamagnetic Iron Oxide Nanoparticles (SPIONs) impregnated in low molecular weight Hyaluronic Acid (HA) forming HA-SPIONs. Our systematic investigation revealed that HA-SPIONs exposed to Rf radiation significantly increased temperature, reaching up to 50 °C. Further testing in tissue-mimicking phantom models also showed consistent heating, with temperatures stabilizing at 43 °C, ideal for localized hyperthermia. The ability of HA-SPIONs to act as an effective localized heating agent when exposed to 27 MHz Rf radiation, reaching apoptosis-inducing temperature, has not been previously reported. In conclusion, synergistic effects of IT-MG in bothin-vitroand tumor-mimicking phantom models demonstrate improved and localized hyperthermia, facilitating adjuvant cancer treatment.
Collapse
Affiliation(s)
- Hema Brindha Masanam
- Department of Biomedical Engineering, SRM Institute of Science and Technology, Kattankulathur-603203, Tamil Nadu, India
| | - Janani Muthuraman
- Department of Biomedical Engineering, SRM Institute of Science and Technology, Kattankulathur-603203, Tamil Nadu, India
| | - Bharath Chandra
- Department of Biomedical Engineering, SRM Institute of Science and Technology, Kattankulathur-603203, Tamil Nadu, India
- School of Biological and Health Systems Engineering, Ira A. Fulton Schools of Engineering, Arizona State University, Tempe, AZ 85281, United States of America
| | | | - Sai Sarath Chandra
- Department of Biomedical Engineering, SRM Institute of Science and Technology, Kattankulathur-603203, Tamil Nadu, India
- Computer Science Engineering, Campbusvile University, Kentucky, KY 42718, United States of America
| | - Piyush Kumar Gupta
- Department of Life Sciences, School of Basic Sciences and Research, Sharda University, Greater Noida 201310, Uttar Pradesh, India
| | - Ashwin Kumar Narasimhan
- Department of Biomedical Engineering, SRM Institute of Science and Technology, Kattankulathur-603203, Tamil Nadu, India
- Department of Biomedical Engineering, College of Engineering and Applied Science, University of Wisconsin, 3200 North Cramer Street, Milwaukee, WI 53211, United States of America
- Acrofluidic Innovations Private Limited, Chennai 600 059, Tamil Nadu, India
| |
Collapse
|
3
|
Gomes SM, Gaspar MM, Coelho JMP, Reis CP. Targeting superficial cancers with gold nanoparticles: a review of current research. Ther Deliv 2024; 15:781-799. [PMID: 39314189 PMCID: PMC11457633 DOI: 10.1080/20415990.2024.2395249] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2024] [Accepted: 08/19/2024] [Indexed: 09/25/2024] Open
Abstract
Superficial cancers typically refer to cancers confined to the surface layers of tissue. Low-targeting therapies or side effects prompt exploration of novel therapeutic approaches. Gold nanoparticles (AuNPs), due to their unique optical properties, serve as effective photosensitizers, enabling tumor ablation through photothermal therapy (PTT). PTT induced by AuNPs can be achieved through light sources externally applied to the skin. Near-infrared radiation is the main light candidate due to its deep tissue penetration capability. This review explores recent advancements in AuNP-based PTT for superficial cancers, specifically breast, head and neck, thyroid, bladder and prostate cancers. Additionally, challenges and future directions in utilizing AuNPs for cancer treatment are discussed, emphasizing the importance of balancing efficacy with safety in clinical applications.
Collapse
Affiliation(s)
- Susana M Gomes
- Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Av. Professor Gama Pinto, 1649-003, Lisboa, Portugal
| | - Maria Manuela Gaspar
- Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Av. Professor Gama Pinto, 1649-003, Lisboa, Portugal
- Instituto de Biofísica e Engenharia Biomédica (IBEB), Faculdade de Ciências, Universidade de Lisboa, Campo Grande, 1749-016, Lisboa, Portugal
| | - João MP Coelho
- Instituto de Biofísica e Engenharia Biomédica (IBEB), Faculdade de Ciências, Universidade de Lisboa, Campo Grande, 1749-016, Lisboa, Portugal
| | - Catarina Pinto Reis
- Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Av. Professor Gama Pinto, 1649-003, Lisboa, Portugal
- Instituto de Biofísica e Engenharia Biomédica (IBEB), Faculdade de Ciências, Universidade de Lisboa, Campo Grande, 1749-016, Lisboa, Portugal
| |
Collapse
|
4
|
Armanetti P, Locatelli I, Venegoni C, Alchera E, Campanella B, Pederzoli F, Maturi M, Locatelli E, Tortorella S, Curnis F, Corti A, Lucianò R, Onor M, Salonia A, Montorsi F, Moschini M, Popov V, Jose J, Comes Franchini M, Ooi EH, Menichetti L, Alfano M. Gold nanorod-assisted theranostic solution for nonvisible residual disease in bladder cancer. Proc Natl Acad Sci U S A 2024; 121:e2411583121. [PMID: 39236242 PMCID: PMC11406305 DOI: 10.1073/pnas.2411583121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2024] [Accepted: 08/06/2024] [Indexed: 09/07/2024] Open
Abstract
Residual nonvisible bladder cancer after proper treatment caused by technological and therapeutic limitations is responsible for tumor relapse and progression. This study aimed to demonstrate the feasibility of a solution for simultaneous detection and treatment of bladder cancer lesions smaller than one millimeter. The α5β1 integrin was identified as a specific marker in 81% of human high-grade nonmuscle invasive bladder cancers and used as a target for the delivery of targeted gold nanorods (GNRs). In a preclinical model of orthotopic bladder cancer expressing the α5β1 integrin, the photoacoustic imaging of targeted GNRs visualized lesions smaller than one millimeter, and their irradiation with continuous laser was used to induce GNR-assisted hyperthermia. Necrosis of the tumor mass, improved survival, and computational modeling were applied to demonstrate the efficacy and safety of this solution. Our study highlights the potential of the GNR-assisted theranostic strategy as a complementary solution in clinical practice to reduce the risk of nonvisible residual bladder cancer after current treatment. Further validation through clinical studies will support the findings of the present study.
Collapse
Affiliation(s)
- Paolo Armanetti
- National Council of Research-Institute of Clinical Physiology, Pisa 56124, Italy
| | - Irene Locatelli
- Division of Experimental Oncology, Urological Research Institute (URI), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele, Milan 20132, Italy
- Department of Urology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan 20132, Italy
| | - Chiara Venegoni
- Division of Experimental Oncology, Urological Research Institute (URI), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele, Milan 20132, Italy
- Department of Urology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan 20132, Italy
| | - Elisa Alchera
- Division of Experimental Oncology, Urological Research Institute (URI), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele, Milan 20132, Italy
- Department of Urology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan 20132, Italy
| | - Beatrice Campanella
- National Research Council (CNR), Institute of Chemistry of Organometallic Compounds, Pisa 56124, Italy
| | - Filippo Pederzoli
- Division of Experimental Oncology, Urological Research Institute (URI), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele, Milan 20132, Italy
- Department of Urology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan 20132, Italy
- Università Vita-Salute San Raffaele, Milan 20132, Italy
| | - Mirko Maturi
- Department of Industrial Chemistry, Toso Montanari, University of Bologna, Bologna 40129, Italy
| | - Erica Locatelli
- Department of Industrial Chemistry, Toso Montanari, University of Bologna, Bologna 40129, Italy
| | - Silvia Tortorella
- Department of Industrial Chemistry, Toso Montanari, University of Bologna, Bologna 40129, Italy
| | - Flavio Curnis
- Division of Experimental Oncology, Tumor Biology and Vascular Targeting Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan 20132, Italy
| | - Angelo Corti
- Division of Experimental Oncology, Tumor Biology and Vascular Targeting Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan 20132, Italy
| | - Roberta Lucianò
- Department of Pathology, Pathology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan 20132, Italy
| | - Massimo Onor
- National Research Council (CNR), Institute of Chemistry of Organometallic Compounds, Pisa 56124, Italy
| | - Andrea Salonia
- Division of Experimental Oncology, Urological Research Institute (URI), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele, Milan 20132, Italy
- Department of Urology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan 20132, Italy
- Università Vita-Salute San Raffaele, Milan 20132, Italy
| | - Francesco Montorsi
- Division of Experimental Oncology, Urological Research Institute (URI), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele, Milan 20132, Italy
- Department of Urology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan 20132, Italy
- Università Vita-Salute San Raffaele, Milan 20132, Italy
| | - Marco Moschini
- Division of Experimental Oncology, Urological Research Institute (URI), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele, Milan 20132, Italy
- Department of Urology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan 20132, Italy
| | - Viktor Popov
- Ascend Technologies Ltd, Southampton SO15 2BG, Hampshire, United Kingdom
| | - Jithin Jose
- FUJIFILM Visualsonics Inc., Amsterdam AB 1114, The Netherlands
| | - Mauro Comes Franchini
- Department of Industrial Chemistry, Toso Montanari, University of Bologna, Bologna 40129, Italy
| | - Ean Hin Ooi
- Medical Engineering and Technology Hub, School of Engineering, Monash University Malaysia, Selangor 47500, Malaysia
| | - Luca Menichetti
- National Council of Research-Institute of Clinical Physiology, Pisa 56124, Italy
| | - Massimo Alfano
- Division of Experimental Oncology, Urological Research Institute (URI), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele, Milan 20132, Italy
- Department of Urology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan 20132, Italy
| |
Collapse
|
5
|
Hossain SMC, Zakaria JB, Ferdows M, Bangalee MZI, Alam MS, Zhao G. Computer simulation-based nanothermal field and tissue damage analysis for cardiac tumor ablation. Med Biol Eng Comput 2024; 62:1549-1567. [PMID: 38308669 DOI: 10.1007/s11517-024-03017-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2023] [Accepted: 01/05/2024] [Indexed: 02/05/2024]
Abstract
Radiofrequency ablation is a nominally invasive technique to eradicate cancerous or non-cancerous cells by heating. However, it is still hampered to acquire a successful cell destruction process due to inappropriate RF intensities that will not entirely obliterate tumorous tissues, causing in treatment failure. In this study, we are acquainted with a nanoassisted RF ablation procedure of cardiac tumor to provide better outcomes for long-term survival rate without any recurrences. A three-dimensional thermo-electric energy model is employed to investigate nanothermal field and ablation efficiency into the left atrium tumor. The cell death model is adopted to quantify the degree of tissue injury while injecting the Fe3O4 nanoparticles concentrations up to 20% into the target tissue. The results reveal that when nanothermal field extents as a function of tissue depth (10 mm) from the electrode tip, the increasing thermal rates were approximately 0.54362%, 3.17039%, and 7.27397% for the particle concentration levels of 7%, 10%, and 15% compared with no-particle case. In the 7% Fe3O4 nanoparticles, 100% fractional damage index is achieved after ablation time of 18 s whereas tissue annihilation approach proceeds longer to complete for no-particle case. The outcomes indicate that injecting nanoparticles may lessen ablation time in surgeries and prevent damage to adjacent healthy tissue.
Collapse
Affiliation(s)
- S M C Hossain
- Department of Applied Mathematics, University of Dhaka, Dhaka, 1000, Bangladesh.
- Department of Electronic Engineering and Information Science, University of Science and Technology of China, Hefei, 230027, China.
| | - J B Zakaria
- Department of Applied Mathematics, University of Dhaka, Dhaka, 1000, Bangladesh
| | - M Ferdows
- Department of Applied Mathematics, University of Dhaka, Dhaka, 1000, Bangladesh
| | - M Z I Bangalee
- Department of Applied Mathematics, University of Dhaka, Dhaka, 1000, Bangladesh
| | - M S Alam
- Department of Mathematics, Jagannath University, Dhaka, 1100, Bangladesh
| | - G Zhao
- Department of Electronic Engineering and Information Science, University of Science and Technology of China, Hefei, 230027, China.
| |
Collapse
|
6
|
Ahmed S, Groenli TM, Lakhan A, Chen Y, Liang G. A reinforcement federated learning based strategy for urinary disease dataset processing. Comput Biol Med 2023; 163:107210. [PMID: 37442008 DOI: 10.1016/j.compbiomed.2023.107210] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2022] [Revised: 06/08/2023] [Accepted: 06/25/2023] [Indexed: 07/15/2023]
Abstract
Urinary disease is a complex healthcare issue that continues to grow in prevalence. Urine tests have proven valuable in identifying conditions such as kidney disease, urinary tract infections, and lower abdominal pain. While machine learning has made significant strides in automating urinary tract infection detection, the accuracy of existing methods is hindered by concerns surrounding data privacy and the time-intensive nature of training and testing with large datasets. Our proposed method aims to address these limitations and achieve highly accurate urinary tract infection detection across various healthcare laboratories, while simultaneously minimizing data security risks and processing delays. To tackle this challenge, we approach the problem as a combinatorial optimization task. We optimize the accuracy objective as a concave function and minimize computation delay as a convex function. Our work introduces a framework enabled by federated learning and reinforcement learning strategy (FLRLS), leveraging lab urine data. FLRLS employs deterministic agents to optimize the exploration and exploitation of urinary data, while the actual determination of urinary tract infections is performed at a centralized, aggregated node. Experimental results demonstrate that our proposed method improves accuracy by 5% and reduces total delay. By combining federated learning, reinforcement learning, and a combinatorial optimization approach, we achieve both high accuracy and minimal delay in urinary tract infection detection.
Collapse
Affiliation(s)
- Saleem Ahmed
- Department of Computer System Engineering, Dawood University of Engineering and Technology, Sindh, Karachi, Pakistan.
| | - Tor-Morten Groenli
- Mobile Technology Laboratory, School of Economics, Innovation and Technology, Kristiania University College, 0153 Oslo, Norway.
| | - Abdullah Lakhan
- Mobile Technology Laboratory, School of Economics, Innovation and Technology, Kristiania University College, 0153 Oslo, Norway; Department of Computer Science and Cybersecurity, Dawood University of Engineering and Technology, Karachi, Sindh, 74800, Pakistan.
| | - Yi Chen
- Key Laboratory of Intelligent Informatics for Safety & Emergency of Zhejiang Province, Wenzhou University, Wenzhou 325035, China.
| | - Guoxi Liang
- Department of Artificial Intelligence, Wenzhou Polytechnic, Wenzhou 325035, China.
| |
Collapse
|
7
|
Cheong JK, Ooi EH, Chiew YS, Menichetti L, Armanetti P, Franchini MC, Alchera E, Locatelli I, Canu T, Maturi M, Popov V, Alfano M. Gold nanorods assisted photothermal therapy of bladder cancer in mice: A computational study on the effects of gold nanorods distribution at the centre, periphery, and surface of bladder cancer. COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE 2023; 230:107363. [PMID: 36720181 DOI: 10.1016/j.cmpb.2023.107363] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/19/2022] [Revised: 01/12/2023] [Accepted: 01/19/2023] [Indexed: 06/18/2023]
Abstract
BACKGROUND AND OBJECTIVES Gold nanorod-assisted photothermal therapy (GNR-PTT) is a cancer treatment whereby GNRs incorporated into the tumour act as photo-absorbers to elevate the thermal destruction effect. In the case of bladder, there are few possible routes to target the tumour with GNRs, namely peri/intra-tumoural injection and intravesical instillation of GNRs. These two approaches lead to different GNR distribution inside the tumour and can affect the treatment outcome. METHODOLOGY The present study investigates the effects of heterogeneous GNR distribution in a typical setup of GNR-PTT. Three cases were considered. Case 1 considered the GNRs at the tumour centre, while Case 2 represents a hypothetical scenario where GNRs are distributed at the tumour periphery; these two cases represent intratumoural accumulation with different degree of GNR spread inside the tumour. Case 3 is achieved when GNRs target the exposed tumoural surface that is invading the bladder wall, when they are delivered by intravesical instillation. RESULTS Results indicate that for a laser power of 0.6 W and GNR volume fraction of 0.01%, Case 2 and 3 were successful in achieving complete tumour eradication after 330 and 470 s of laser irradiation, respectively. Case 1 failed to form complete tumour damage when the GNRs are concentrated at the tumour centre but managed to produce complete tumour damage if the spread of GNRs is wider. Results from Case 2 also demonstrated a different heating profile from Case 1, suggesting that thermal ablation during GNR-PTT is dependant on the GNRs distribution inside the tumour. Case 3 shows similar results to Case 2 whereby gradual but uniform heating is observed. Cases 2 and 3 show that uniformly heating the tumour can reduce damage to the surrounding tissues. CONCLUSIONS Different GNR distribution associated with the different methods of introducing GNRs to the bladder during GNR-PTT affect the treatment outcome of bladder cancer in mice. Insufficient spreading during intratumoural injection of GNRs can render the treatment ineffective, while administered via intravesical instillation. GNR distribution achieved through intravesical instillation present some advantages over intratumoural injection and is worthy of further exploration.
Collapse
Affiliation(s)
- Jason Kk Cheong
- Ascend Technologies Ltd, Wessex House, Upper Market Street, Eastleigh, SO50 9FD, United Kingdom; Mechanical Engineering Discipline, School of Engineering and Advanced Engineering Platform, Monash University Malaysia, Jalan Lagoon Selatan, 47500 Bandar Sunway, Selangor Malaysia
| | - Ean H Ooi
- Ascend Technologies Ltd, Wessex House, Upper Market Street, Eastleigh, SO50 9FD, United Kingdom; Mechanical Engineering Discipline, School of Engineering and Advanced Engineering Platform, Monash University Malaysia, Jalan Lagoon Selatan, 47500 Bandar Sunway, Selangor Malaysia.
| | - Yeong S Chiew
- Mechanical Engineering Discipline, School of Engineering and Advanced Engineering Platform, Monash University Malaysia, Jalan Lagoon Selatan, 47500 Bandar Sunway, Selangor Malaysia
| | - Luca Menichetti
- CNR - Istituto di Fisiologia Clinica, Sede principale, Via G. Moruzzi 1, 56124 Pisa, Italy
| | - Paolo Armanetti
- CNR - Istituto di Fisiologia Clinica, Sede principale, Via G. Moruzzi 1, 56124 Pisa, Italy
| | - Mauro Comes Franchini
- Department of Industrial Chemistry Toso Montanari, University of Bologna, Viale Risorgimento 4, 40136 Bologna, Italy
| | - Elisa Alchera
- Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Via Olgettina 60, 20132 Milan, Italy
| | - Irene Locatelli
- Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Via Olgettina 60, 20132 Milan, Italy
| | - Tamara Canu
- Experimental Imaging Center, Preclinical Imaging Facility, IRCCS San Raffele Scientific Institute, 20132 Milan, Italy
| | - Mirko Maturi
- Department of Industrial Chemistry Toso Montanari, University of Bologna, Viale Risorgimento 4, 40136 Bologna, Italy
| | - Viktor Popov
- Ascend Technologies Ltd, Wessex House, Upper Market Street, Eastleigh, SO50 9FD, United Kingdom
| | - Massimo Alfano
- Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Via Olgettina 60, 20132 Milan, Italy
| |
Collapse
|
8
|
Cheng J, Zhang S, Fan A, Li Y, Xu P, Huang J, He M, Wang H. An immune-related gene signature for the prognosis of human bladder cancer based on WGCNA. Comput Biol Med 2022; 151:106186. [PMID: 36335813 DOI: 10.1016/j.compbiomed.2022.106186] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2022] [Revised: 08/30/2022] [Accepted: 10/08/2022] [Indexed: 12/27/2022]
Abstract
The innovation of immunotherapy was a milestone in the treatment of bladder cancer (BLCA). However, the treatment benefits varied by individual thus promoting the investigation of the biomarker of the patients. Unfortunately, there were not many effective predictive models, which were desired by clinicians, for BLCA that can predict the prognosis and benefit of immunotherapy. We constructed a three genes prognosis prediction model termed RiskScore based on the result of weighted correlation network analysis (WGCNA) from The Cancer Genome Atlas (TCGA) cohort (n = 406). We then validated the prediction accuracy with three validation cohort(GSE13507 (n = 165), GSE48075(n = 73), GSE32894(n = 224)). We compared the differences in gene expression, immune relate function, and immune infiltration between two groups divided by RiskScore. We further discovered the potential drug target and suitable compounds for high-risk groups. Our results suggested that the low-risk group may be more potential for immunotherapy for they have higher B cell infiltration, higher expression of immune checkpoints(PDCD1, CTLA4), and much more active immune-related pathways(B cell and T cell receptor signaling pathway). The RiskScore showed a well predictive accuracy for the prognosis of BLCA. After Spearman analysis, we found the suitable drug target and compounds for the patients in the high-risk group. The model we constructed is able to predict the prognosis of BLCA patients with ease and accuracy. PLK1 and gefitinib may be utilized for further treatment of BLCA patients.
Collapse
Affiliation(s)
- Jiangting Cheng
- Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China
| | - Sihong Zhang
- Department of Urology, Xuhui Hospital, Fudan University, Shanghai, China
| | - Aoyu Fan
- Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China
| | - Yaohui Li
- Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China
| | - Peirong Xu
- Department of Urology, Xuhui Hospital, Fudan University, Shanghai, China
| | - Jiaqi Huang
- Department of Urology, Minhang Hospital, Fudan University, Shanghai, China
| | - Minke He
- Department of Urology, Minhang Hospital, Fudan University, Shanghai, China
| | - Hang Wang
- Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
| |
Collapse
|
9
|
Alchera E, Monieri M, Maturi M, Locatelli I, Locatelli E, Tortorella S, Sacchi A, Corti A, Nebuloni M, Lucianò R, Pederzoli F, Montorsi F, Salonia A, Meyer S, Jose J, Giustetto P, Franchini MC, Curnis F, Alfano M. Early diagnosis of bladder cancer by photoacoustic imaging of tumor-targeted gold nanorods. PHOTOACOUSTICS 2022; 28:100400. [PMID: 36386292 PMCID: PMC9649962 DOI: 10.1016/j.pacs.2022.100400] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 12/21/2021] [Revised: 06/30/2022] [Accepted: 08/29/2022] [Indexed: 06/16/2023]
Abstract
Detection and removal of bladder cancer lesions at an early stage is crucial for preventing tumor relapse and progression. This study aimed to develop a new technological platform for the visualization of small and flat urothelial lesions of high-grade bladder carcinoma in situ (CIS). We found that the integrin α5β1, overexpressed in bladder cancer cell lines, murine orthotopic bladder cancer and human bladder CIS, can be exploited as a receptor for targeted delivery of GNRs functionalized with the cyclic CphgisoDGRG peptide (Iso4). The GNRs@Chit-Iso4 was stable in urine and selectively recognized α5β1 positive neoplastic urothelium, while low frequency ultrasound-assisted shaking of intravesically instilled GNRs@Chit-Iso4 allowed the distribution of nanoparticles across the entire volume of the bladder. Photoacoustic imaging of GNRs@Chit-Iso4 bound to tumor cells allowed for the detection of neoplastic lesions smaller than 0.5 mm that were undetectable by ultrasound imaging and bioluminescence.
Collapse
Affiliation(s)
- Elisa Alchera
- Unit of Urology, URI, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Matteo Monieri
- Tumor Biology and Vascular Targeting Unit, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Mirko Maturi
- Department of Industrial Chemistry "Toso Montanari", University of Bologna, Bologna, Italy
| | - Irene Locatelli
- Unit of Urology, URI, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Erica Locatelli
- Department of Industrial Chemistry "Toso Montanari", University of Bologna, Bologna, Italy
| | - Silvia Tortorella
- Department of Industrial Chemistry "Toso Montanari", University of Bologna, Bologna, Italy
| | - Angelina Sacchi
- Tumor Biology and Vascular Targeting Unit, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Angelo Corti
- Tumor Biology and Vascular Targeting Unit, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy
- Università Vita-Salute San Raffaele, Milan, Italy
| | - Manuela Nebuloni
- Pathology Unit, Department of Biomedical and Clinical Sciences, L. Sacco Hospital, Università degli Studi di Milano, Milan, Italy
| | - Roberta Lucianò
- Department of Pathology, IRCCS San Raffaele Hospital and Scientific Institute, Milan, Italy
| | - Filippo Pederzoli
- Unit of Urology, URI, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy
- Università Vita-Salute San Raffaele, Milan, Italy
| | - Francesco Montorsi
- Unit of Urology, URI, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy
- Università Vita-Salute San Raffaele, Milan, Italy
| | - Andrea Salonia
- Unit of Urology, URI, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy
- Università Vita-Salute San Raffaele, Milan, Italy
| | - Sandra Meyer
- FUJIFILM Visualsonics Inc., Amsterdam, the Netherlands
| | - Jithin Jose
- FUJIFILM Visualsonics Inc., Amsterdam, the Netherlands
| | | | - Mauro Comes Franchini
- Department of Industrial Chemistry "Toso Montanari", University of Bologna, Bologna, Italy
| | - Flavio Curnis
- Tumor Biology and Vascular Targeting Unit, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Massimo Alfano
- Unit of Urology, URI, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy
| |
Collapse
|
10
|
Gold Nanorod-Assisted Photothermal Therapy and Improvement Strategies. Bioengineering (Basel) 2022; 9:bioengineering9050200. [PMID: 35621478 PMCID: PMC9138169 DOI: 10.3390/bioengineering9050200] [Citation(s) in RCA: 37] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2022] [Revised: 04/22/2022] [Accepted: 04/28/2022] [Indexed: 11/17/2022] Open
Abstract
Noble metal nanoparticles have been sought after in cancer nanomedicine during the past two decades, owing to the unique localized surface plasmon resonance that induces strong absorption and scattering properties of the nanoparticles. A popular application of noble metal nanoparticles is photothermal therapy, which destroys cancer cells by heat generated by laser irradiation of the nanoparticles. Gold nanorods have stood out as one of the major types of noble metal nanoparticles for photothermal therapy due to the facile tuning of their optical properties in the tissue penetrative near infrared region, strong photothermal conversion efficiency, and long blood circulation half-life after surface modification with stealthy polymers. In this review, we will summarize the optical properties of gold nanorods and their applications in photothermal therapy. We will also discuss the recent strategies to improve gold nanorod-assisted photothermal therapy through combination with chemotherapy and photodynamic therapy.
Collapse
|